<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2-813-12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ELIDEL 1% CREAM
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PIMECROLIMUS
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        %
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Topical
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Cream
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tube
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        63.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MEDA Manufacturing" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MEDA Manufacturing
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 411]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Import Company - BANAJA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MEDA PHARMA GmbH & Co KG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        D11AX15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Elidel cream contains a medicine called<br />pimecrolimus.<br />It does not contain any steroids.</p><p>Elidel cream specifically treats an inflammation<br />of the skin called atopic dermatitis (eczema).<br />It works in the cells in the skin that cause the<br />inflammation and characteristic redness and<br />itching of eczema.<br />The cream is used to treat signs and<br />symptoms of mild or moderate eczema (e.g.<br />redness and itch) in children (aged 2 years<br />and above), teenagers and adults When used<br />to treat early signs and symptoms it can<br />prevent progression to severe flare-ups.<br />Elidel cream is for use only after other prescription<br />medicines or emollients have not<br />worked for you or if your doctor recommends<br />that other prescription medicines should not<br />be used.<br />You must talk to a doctor if you do not feel<br />better or if you feel worse after 42 days.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Carefully follow all instructions given to you<br />by your doctor.<br />Read the following information before you use<br />Elidel cream.<br />Do not use Elidel cream:<br />&ndash; if you are allergic to Pimecrolimus or any<br />of the other ingredients of this medicine<br />(listed in section 6).<br />Take special care with Elidel cream<br />Elidel is not approved for children<br />younger than 2 years of age. Therefore it<br />should not be used in this age group. Please<br />consult your doctor.<br />Warnings and precautions<br />Speak to your doctor before using Elidel if<br />you have a weakened immune system<br />(immuno-compromised) whatever the cause.</p><p>Elidel cream is only to be used for atopic<br />dermatitis. Do not use for other skin<br />conditions.<br />Elidel cream is for external use only. Do<br />not use it in your nose, eyes or mouth. If<br />accidentally applied to these areas, the cream<br />should be thoroughly wiped off and/or rinsed<br />with water. You should take care not to<br />swallow it, or to accidentally transfer it into<br />your mouth when, for example, it is applied<br />to the hands.<br />Do not apply the cream to areas of the<br />skin affected by active viral infection<br />such as cold sores (herpes simplex) or<br />chicken pox.<br />If your skin is infected, check with your<br />doctor before using Elidel. Your doctor<br />may ask you to use an appropriate medicine<br />to treat the infection. When the infection at<br />treatment sites is cleared, treatment with<br />Elidel can be started. If your skin becomes<br />infected during treatment with Elidel, you<br />should inform your doctor. Your doctor may<br />ask you to stop using Elidel until the infection<br />has been adequately controlled.<br />Elidel may be associated with an increased<br />risk of a severe herpes simplex skin infection<br />(eczema herpeticum). Therefore if you develop<br />painful sores anywhere on your body, tell<br />your doctor immediately. You should stop<br />using Elidel until the infection has cleared.<br />Elidel may cause reactions at the application<br />site such as a feeling of warmth<br />and/or a burning sensation. These reactions<br />are usually mild and last only for a short time.<br />Tell your doctor immediately if you have a<br />severe reaction to Elidel.<br />If you are using Elidel, do not cover the<br />treated skin with bandages, dressings or&nbsp;wraps. However, you can still wear normal<br />clothing.<br />Avoid excessive exposure to sunlight, sun<br />lamps and tanning beds during treatment<br />with Elidel. If you are outdoors after applying<br />Elidel, wear loose fitting clothing, use appropriate<br />sunscreen products and minimise the<br />amount of time you spend in the sun. If you<br />have erythroderma (redness of almost the<br />entire body) or a skin condition called<br />Netherton&rsquo;s syndrome, speak to your doctor<br />before you start using Elidel.<br />Also speak to your doctor before using Elidel<br />if you have any skin malignancies<br />(tumours). If your lymph nodes become<br />swollen during treatment with Elidel cream,<br />tell your doctor.<br />Children<br />The use of Elidel in patients under 2 years of<br />age is not recommended until further data<br />become available.<br />Other medicines and Elidel cream<br />Tell your doctor or pharmacist if you are<br />taking, have recently taken or might take any<br />other medicines.<br />Application of pimecrolimus to vaccination<br />sites, as long as local reactions persist is not<br />recommended.<br />If you have extensive eczema, you may need<br />to stop using Elidel before having any vaccinations.<br />Your doctor will be able to tell you if<br />this is necessary.<br />Elidel should not be used at the same time<br />as ultraviolet light treatments (such as UVA,<br />PUVA, UVB) or systemic immunosuppressive<br />medicines (such as azathioprine or<br />cyclosporin).<br />Interactions with other medicines that you<br />take are unlikely to occur</p><p>Elidel cream with food, drink and<br />alcohol<br />In rare cases, you may experience flushing,<br />rash, burning, itching or swelling shortly after<br />drinking alcohol.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding,<br />think you may be pregnant or are<br />planning to have a baby, ask your doctor<br />or pharmacist for advice before taking<br />this medicine.<br />You should not use Elidel if you are pregnant.<br />It is not known whether the active substance<br />in Elidel passes into the milk after application<br />to the skin. Do not apply Elidel to the breasts<br />if breast-feeding.<br />Driving and using machines<br />Elidel has no known effect on the ability to<br />drive or use machines.<br />Elidel cream contains cetyl alcohol and<br />stearyl alcohol which may cause local<br />skin reactions. Elidel also contains<br />propylene glycol, which may cause skin<br />irritation..</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as<br />your doctor or pharmacist has told<br />you. Check with your doctor or<br />pharmacist if you are not sure.<br />You can use Elidel on all skin areas, including<br />the head, face and neck and in the folds of<br />the skin.<br />Apply the cream as follows:<br />&bull; Wash and dry your hands.<br />&bull; Open the tube (the first time you use the<br />tube you will need to break the seal using<br />the spike in the top of the cap).<br />&bull; Squeeze the cream onto your finger.</p><p>cream with food, drink and<br />alcohol<br />In rare cases, you may experience flushing,<br />rash, burning, itching or swelling shortly after<br />drinking alcohol.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding,<br />think you may be pregnant or are<br />planning to have a baby, ask your doctor<br />or pharmacist for advice before taking<br />this medicine.<br />You should not use Elidel if you are pregnant.<br />It is not known whether the active substance<br />in Elidel passes into the milk after application<br />to the skin. Do not apply Elidel to the breasts<br />if breast-feeding.<br />Driving and using machines<br />Elidel has no known effect on the ability to<br />drive or use machines.<br />Elidel cream contains cetyl alcohol and<br />stearyl alcohol which may cause local<br />skin reactions. Elidel also contains<br />propylene glycol, which may cause skin<br />irritation.<br />3. How to apply Elidel cream<br />Always use this medicine exactly as<br />your doctor or pharmacist has told<br />you. Check with your doctor or<br />pharmacist if you are not sure.<br />You can use Elidel on all skin areas, including<br />the head, face and neck and in the folds of<br />the skin.<br />Apply the cream as follows:<br />&bull; Wash and dry your hands.<br />&bull; Open the tube (the first time you use the<br />tube you will need to break the seal using<br />the spike in the top of the cap).<br />&bull; Squeeze the cream onto your finger.<br />&bull; Apply a thin layer of Elidel and completely<br />cover the affected skin.<br />&bull; Apply only on areas affected with eczema<br />&bull; Rub in gently and fully.<br />&bull; Replace the cap on the tube.<br />The cream should be applied twice daily,<br />for instance once in the morning and once in<br />the evening. You can use moisturisers<br />(emollients) with Elidel. If you use<br />moisturisers, they should be applied<br />immediately after Elidel.<br />Do not bath, shower or swim right after<br />applying Elidel. This could wash off the<br />cream.<br />How long to apply Elidel<br />Long term treatment should be intermittent<br />and not continuous. Stop Elidel as soon as<br />signs of eczema have disappeared.<br />Continue using the cream for as long as your<br />doctor advises.<br />Stop the treatment and consult your doctor<br />if no improvement occurs after 6 weeks<br />or if your eczema gets worse.<br />In the long-term treatment of eczema, begin<br />using Elidel as soon as you notice signs and<br />symptoms (redness and itch). This helps to<br />prevent progression to severe flare-ups.<br />If signs and symptoms return you should<br />start treatment again.<br />If you use more Elidel cream than<br />you should<br />If you apply more cream to your skin than you<br />needed to, just wipe it off.<br />If you forget to use Elidel cream<br />If you forget an application of the cream,<br />apply it as soon as possible and then continue<br />your normal dosing routine. However, if it<br />alsmost time for your next application, skip<br />the missed dose and&nbsp;continue your normal dosing routine. Do not<br />apply extra cream to ake up for a missed dose.<br />If you stop using Elidel cream<br />If you have any further questions on the use of<br />this medicine, ask your doctor or pharmacist.<br />If you accidentally swallow some<br />Elidel<br />If you or someone else accidentally swallows<br />Elidel, tell your doctor immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause<br />side effects, although not everybody gets them.<br />The most common side effects of Elidel are<br />reactions (such as discomfort) at the<br />application site. Such reactions are generally<br />mild/moderate, occur early in treatment and<br />last only for a short time.<br />Some effects could be serious<br />Rare side effects (affecting less than 1 in<br />1000 people)<br />&bull; angioedema &ndash; the signs include itching,<br />hives (urticaria), red marks on the hands,<br />feet and throat, swelling of the throat and<br />tongue, swelling around the eyes and lips,<br />difficulty breathing and swallowing.<br />Very rare side-effects (affecting less than<br />1 in 10,000 people)<br />&bull; anaphylactic reaction: skin rash including<br />red itchy skin, swelling of the hands, feet,<br />ankles, face, lips, mouth or throat (these<br />symptoms are also described as angioedema<br />and may cause difficulty in<br />swallowing or breathing) and you may feel<br />you are going to faint.<br />If you experience any of these symptoms<br />soon after using Elidel cream, stop using<br />the cream and tell your doctor<br />immediately.</p><p>Other side effects may include<br />Very common side effects (affecting more<br />than 1 in 10 people)<br />&bull; A feeling of warmth and/or burning at the<br />application site.<br />Common side-effects (affecting more than<br />1 in 100 people)<br />&bull; Irritation, itching and reddening of the skin<br />where the cream has been applied.<br />&bull; Skin infections (such as folliculitis).<br />Uncommon side effects (affecting less than<br />1 in every 100 people)<br />&bull; Skin infections such as impetigo (a bacterial<br />skin infection), cold sores (herpes<br />simplex), shingles (herpes zoster), herpes<br />simplex dermatitis (eczema herpeticum),<br />molluscum contagiosum (a viral skin<br />infection), warts and furuncles (boils).<br />&bull; Application site reactions such as rash,<br />pain, prickling sensation, slight scaling of<br />the skin, dryness, swelling and worsening<br />of eczema symptoms.<br />Rare side effects (affecting less than 1 in<br />1000 people)<br />&bull; Flushing, rash, burning, itching or swelling<br />shortly after drinking alcohol.<br />&bull; Changes in the skin color (becomes darker<br />or lighter than the surrounding skin).<br />Cases of cancer, including cancer of the<br />lymph glands or skin, have been reported in<br />patients using Elidel.<br />Cases of enlarged lymph glands have been<br />reported in patients using Elidel. However, a<br />link to the treatment with Elidel cream has<br />not been established.<br />If any of the side effects gets severe, or if<br />you notice any side effects not mentioned in<br />this leaflet, please tell your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach<br />of children.<br />Do not use this medicine after the expiry date<br />which is stated on the carton and tube. The<br />expiry date refers to the last day of that<br />month.<br />Store below 30&deg;C. Do not freeze.<br />Store in the original package. Keep the tube<br />tightly closed.<br />Once opened, the tube should be used within<br />6 months. You may find it helpful to write the<br />date you opened the tube in the space<br />provided on the carton.<br />Do not throw away any medicines via<br />wastewater. Ask your pharmacist how to<br />throw away medicines you no longer use.<br />These measures will help protect the<br />environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Elidel cream contains<br />&ndash; The active substance is Pimecrolimus.<br />1 gram of Elidel cream contains 10mg of<br />pimecrolimus.<br />&ndash; The other ingredients aremedium chain<br />triglycerides, oleyl alcohol, propylene<br />glycol, stearyl alcohol, cetyl alcohol,<br />mono- and di-glycerides,<br />sodium cetostearyl sulphate, benzyl<br />alcohol, citric acid anhydrous, sodium<br />hydroxide, purified water.<br />What Elidel cream looks</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Elidel is a whitish, odourless, non-staining
and easily spreadable cream. The cream is
available in tubes of 5g, 15 g, 30 g, 60 g and 100 g. Not all packsizes are necessarily
available in your country.
This is a medicament
• A medicament is a product which affects
your health, and its consumption contrary to
instructions is dangerous for you.
• Follow strictly the doctor’s prescription, the
method of use and the instructions of the
pharmacist who sold the medicament.
• The doctor and the pharmacist are experts
in medicine, its benefits and risks.
• Do not by yourself interrupt the period of
treatment prescribed for you.
• Do not repeat the same prescription without
consulting your doctor.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Council of Arab Health Ministers<br />Union of Arab Pharmacists<br />Marketing Authorisation Holder<br />MEDA Pharma GmbH &amp; Co. KG,<br />Benzstrasse 1, 61352 Bad Homburg, Germany<br />Manufacturer<br />MEDA Manufacturing<br />Avenue J. F. Kennedy<br />33700 M&eacute;rignac<br />France</p><p>To report any side effects:<br />The National Pharmacovigilance and Drug<br />Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                11/2013
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي إيليدل كريم علي مستحضر دوائي يطلق عليه بيميكروليموس؛ إنه لا يحتوي على أي من مركبات الكورتيزون (ستيرويدات)؛ إن<br />إيليدل كريم يعالج أحد أنواع الالتهابات الجلدية التي يطلق عليها التهاب الجلد التأتبي (الأكزيما) حيث يعمل داخل خلايا البشرة التي تسبب<br />الالتهاب و الاحمرار الواضح و حكة الأكزيما.<br />يستخدم الكريم لعلاج امراض الأكزيما الخفيفة إلي المتوسطة (مثل الاحمرار و الحكة)<br />عند الأطفال (عمر سنتين فأكثر) و المراهقين و الكبار؛ وعند استخدامه لمعالجة الأعراض المبكرة فإنه يمكن أن يحول دون تطور<br />الالتهاب إلي درجة حادة.<br />بمكن استخدام إيليدل كريم فقط في حالة عدم فاعلية الأدوية أو المرطبات الموصوفة الأخرى أو إذا أوصى طبيبك بعدم استخدام الأدوية<br />الموصوفة الأخرى.<br />بجب عليك التشاور مع طبيبك في حالة عدم شعورك بتحسن أو إذ شعرت بتدهور الحالة بعد ٤٢ يوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-إذا كنت تعاني من أي حساسية تجاه مستحضرات بيميكروليموس أو أي مكونات أخري في هذا الدواء (المكونات مذكورة في القسم رقم<br />(٦<br />توخي الحذر الشديد عند استخدام ايليدل كريم<br />إيليدل كريم لا يناسب الأطفال أقل من سنتين؛ و من ثم ينبغي عدم استخدامه مع هذه الفئة العمرية؛ يرجى الرجوع إلي طبيبك المعالج.<br />تحذيرات و احتياطات<br />استشر طبيبك قبل استخدام إيليدل إذا كان جهازك المناعي ضعيفا (قلة المناعة) لأي سبب من الأسباب.<br />إيليدل كريم صالح في الأستخدام فقط في حالة التهاب الجلد التأتبي؛ لا تستخدمه لأي أغراض جلدية أخرى.<br />إيليدل كريم صالح للاستخدام الخارجي فقط؛ لا تستخدمه داخل أنفك أو عينيك أو فمك؛ وإذا تم وضعه علي هذه المناطق بصورة<br />عارضة، ينبغي مسح الكريم تماما أو شطف المكان بالماء؛ يجب الحرص علي عدم بلعه، أوانتقاله بصورة عارضة إلي فمك، عند وضعه<br />علي اليدين، علي سبيل المثال.<br />لا تضع الكريم علي مناطق البشرة المصابة بعدوى فيروسية نشطة، مثل القروح الباردة أو الجديري المائي.<br />وإذا كانت بشرتك مصابة بعدوي يرجى استشارة طبيبك قبل استخدام إيليدل؛ قد يطلب منك طبيبك استخدام علاجا مناسباً لعلاج العدوى و<br />بعد التعافي من تلك الإصابة، يمكن البدء في استخدام إيليدل؛ و إذا أصيبت بشرتك أثناء العلاج بإيليدل. ينبغي عليك أن تخبر طبيبك؛ قد<br />يطلب منك طبيبك إيقاف استخدام إيليدل حتي يتم السيطرة علي العدوي.<br />قد يظهر خطر متزايد بالإصابة بمرض العقبول البسيط (الأكزيما العقبولية) أثناء العلاج بإيليدل؛ ومن ثم إذا ظهرت لديك تقرحات مؤلمة<br />في أي مكان في جسدك، اخبر طبيبك علي الفور؛ ينبغي عليك إيقاف استخدام إيليدل حتي التعافي من الإصابة.</p><p>قد يؤدي إيليدل إلي حدوث تفاعلات في موضع العلاج، مثل الشعور بالحرارة او الحرقان؛ عادةً ما تكون هذه التفاعلات بسيطة، و تستمر<br />لفترات قصيرة.<br />اخبر طبيبك علي الفور، في حالة حدوث تفاعل حاد مع إيليدل.<br />عند استخدام إيليدل، لا تغطي البشرة المعالجة بشاش أو ضمادات؛ و بإمكانك الاستمرار في ارتداء الملابس العادية.<br />تجنب التعرض الزائد لضوء الشمس و المصابيح الشمسية و حمامات الشمس أثناء العلاج بإيليدل؛ إذا خرجت من المنزل بعد استخدام<br />إيليدل. قم بارتداء ملابس واسعة، واستخدام منتجات واقية من الشمس مناسبة و تقليل فترة تعرضك لأشعة الشمس؛<br />وإذا كنت تعاني من احمرار البشرة (احمرار الجسد بالكامل تقريباً) أو متلازمة نيثيرتون التي تصيب البشرة. استشر طبيبك قبل البدء في<br />استخدام إيليدل<br />تحدث أيضا مع طبيبك قبل استخدام إيليدل إذا كنت تعاني من أي أورام خبيثة في البشرة؛ و إذا تورمت غددك الليمفاوية أثتاء العلاج<br />بإيليدل كريم، اخبر طبيبك.<br />الأطفال<br />لا يوصي باستخدام إيليدل مع المرضي الذين يقل عمرهم عن سنتين حتي يتم التوصل إلي قدر أكثر من المعلومات حيال ذلك.<br />الأدوية الأخرى و إيليدل كريم<br />قم بإخبار طبيبك أو الصيدلي إذا كنت تتعاطي أي أدوية أخرى أو إذا كنت مؤخراً قد تعاطيت أو تنوي أخذ أي أدوية أخري.<br />لا يوصي باستخدام بيميكروليموس في أماكن التطعيم في حالة وجود التفاعلات الموضعية الناتجة عن التطعيم.<br />إذا كنت تعاني من أكزيما في مساحات كبيرة من الجسم فقد ينبغي عليك التوقف عن استخدام إيليدل قبل استخدام أي لقاحات؛ و سوف<br />يشير عليك طبيبك إذا كان ذلك ضروريا أم لا.<br />ينبغي عدم تزامن استخدام إيليدل مع أي علاجات بالأشعة فوق البنفسجية (مثل الأشعة فوق البنفسجية أ ، بوفا ، الأشعة فوق البنفسجية<br />ب) أو الأدوية المثبطة للمناعة النظامية (مثل الآزاثيوبرين أو السيكلوسبورين) قليلاً ما تحدث تفاعلات مع الأدوية الأخرى التي<br />تتعاطاها.<br />استخدام إيليدل كريم مع الأطعمة و المشروبات و الكحوليات<br />في حالات نادرة، قد تواجه احمرار أو طفح جلدي أو حرقان أو حكة أو تورم بعد فترة قصيرة من تناول الكحوليات.<br />الحمل و الرضاعة<br />إذا كنتِ حامل أو مرضعة أو من المحتمل أن تكوني حاملا أو تخططين للحمل أو تخططين للولادة، استشيري طبيبك أو الصيدلي قبل<br />البدء في هذا العلاج.<br />ينبغي عدم استخدام إيليدل أثناء الحمل.<br />لم يتم التوصل إلي ما إذا كانت المادة الموجودة في إيليدل تتسرب إلي لبن الرضاعة بعد استعماله علي البشرة أم لا؛ لا تضعي إيليدل علي<br />الثدي إذا كنتِ مرضعة.<br />القيادة واستخدام الماكينات<br />ليس لإيليدل أي آثار معروفة علي إمكانية القيادة أو استخدام الماكينات.<br />يحتوي إيليدل كريم علي سيتيل الكحول و ستياريل الكحول اللذان قد يتسببان في تفاعلات علي البشرة؛ كما يحتوي إيليدل أيضا علي<br />غليكول البروبيلين الذي قد يسبب تهيج الجلد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>استخدم هذا الدواء وفقا لتعليمات طبيبك او الصيدلي؛ استشر طبيبك أو الصيدلي إذا لم تكن متأكدا يمكنك استخدام إيليدل علي جميع<br />مناطق البشرة، بما في ذلك الرأس و الوجه و الرقبة و في ثنايا الجلد.<br />ضع الكريم كالتالي:<br />&bull;اغسل يديك و جففهما.<br />&bull;افتح الانبوبة (إذا كانت هذه هي المرة الأولى التي تستخدم فيها الأنبوبة، فإنك ستحتاج إلي كسر القفل باستخدام الجزء البارز الموجود<br />أعلي الغطاء)<br />&bull;اضغط علي الأنبوبة بأصابعك لإخراج الكريم.<br />&bull;ضع طبقة رقيقة من إيليدل علي البشرة وغطِ تماماً البشرة المصابة بالأكزيما فقط.<br />&bull;ادعكه بلطف علي المنطقة بالكامل.<br />&bull;غطِ الأنبوبة بالغطاء.</p><p>ينبغي استخدام الكريم مرتين يومي ا،ً علي سبيل المثال مرة صباحا ومرة مساءً؛ كما يمكن استخدام الكريمات المرطبة (المرطبات) مع<br />إيليدل؛ في حالة استخدام المرطبات، ينبغي وضعها بعد إيليدل مباشرة . لا تستحم او تسبح فورا بعد وضع إيليدل حيث إن هذا قد يتسبب<br />في زوال الكريم من علي البشرة.<br />فترة استعمال إيليدل<br />ينبغي أن يكون العلاج طويل المدى متقطعاً و غير متواصل؛ توقف عن استخدام إيليدل فور اختفاء أعراض الأكزيما. استمر في استخدام<br />الكريم طوال الفترة التي يوصي طبيبك بها.<br />توقف عن استخدام العلاج واستشر طبيبك في حالة عدم ظهور أي تحسن بعد ٦ اسابيع أو إذا ساءت حالة الأكزيما.<br />في حالات علاج الأكزيما طويل المدى، ابدأ في استخدام إيليدل فور ملاحظتك للأعراض ( الاحمرار و الحكة)، هذا يساعد علي منع<br />تطور الحالة و زيادة حدتها؛ وفي حالة عودة ظهور أعراض الأعراض، ينبغي البدء في استخدام العلاج مرة أخرى.<br />إذا استخدمت إيليدل كريم أكثر مما ينبغي<br />في حالة وضغ كمية إيليدل أكبر من المطلوبة علي بشرتك، امسحها فقط.<br />إذا نسيت استخدام إيليدل كريم<br />إذا نسيت وضع الكريم، ضعه في أقرب وقت ممكن ثم استمر في وضع جرعتك المعتادة؛ ومع ذلك، إذا كان وقت جرعتك التالية قد حان،<br />تجاهل الجرعة التي نسيتها و استمر في وضع الجرعة المعتادة؛ لا تضع كمية إضافية من الكريم لتعويض الجرعة التي نسيتها.<br />إذا توقفت عن استخدام إيليدل كريم<br />في حالة وجود أي استفسارات أخري بشأن استخدام هذا العلاج، اطرحها علي طبيبك او الصيدلي.<br />إذا بلعت إيليدل عن طريق الخطا<br />إذا بلعت أنت أو أي شخص آخر إيليدل عن طريق الخطأ، اخبر طبيبك علي الفور</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثله مثل أي دواء آخر، قد يسبب هذا الدواء آثاراً جانبية، علي الرغم من انها قد لا تظهر لدى الجميع.<br />أكثر الآثار الجانبية التي يسببها إيليدل شيوعا تتمثل في تقاعلات موضعية (مثل انزعاج) في موضع العلاج؛ إلا أن هذه التفاهلات تعتبر<br />بصفة عامة خفيفة/متوسطة، وتحدث في مرحلة مبكرة من العلاج وتستمر لفترة قصيرة.<br />بعض الآثار الجانبية قد تكون خطيرة<br />آثار جانبية نادرة (تظهر لدى أقل من ١ من كل ١٠٠٠ شخص):<br />&bull;الوذمة الوعائية : و تتضمن الأعراض حكة و احمرار، وعلامات حمراء علي اليدين و القدمين و الحلق، و تورم في الحلق و اللسان، و<br />تورم حول العينين والشفتين، وصعوبة في التنفس و البلع.<br />آثار جانبية نادرة جداً ( تظهر لدى اقل من ١ من كل ١٠٬٠٠٠ شخص):<br />&bull;التفاعلات التحسسية : طفح جلدي يشتمل علي الحكة واحمرار في البشرة، و تورم في اليدين أو القدمين أو الكاحلين أو الوجه أو الشفتين<br />أو الفم أو الحلق (كما توصف هذه الأعراض أيضا بأنها وذمة وعائية ويمكن ان تسبب صعوبة في البلع أو التنفس)، كما أن الشخص قد<br />يشعر بأنه علي وشك أن يسقط مغشيا عليه.<br />إذا واجهت أياً من هذه الأعراض بعد استخدام إيليدل كريم مباشرةً، توقف عن استخدامه و اخبر طبيبك علي الفور.<br />قد تشتمل الآثار الجانبية الأخري علي:<br />آثار جانبية شديدة الشيوع (تؤثر علي أكثر من ١ من كل ١٠ أشخاص)<br />&bull;شعور بالحرارة أو الحرقان في موضع الاستخدام.<br />آثار جانبية شائعة (تؤثر علي أكثر من ١ من كل ١٠٠ شخص)<br />&bull;تهيج وحكة و احمرار في البشرة في موضع استخدام الكريم.<br />&bull;التهابات جلدية (مثل التهاب الأجربة)<br />آثار جانبية غير شائعة (تؤثر علي أقل من ١من كل ١٠٠ شخص)<br />&bull;التهابات جلدية مثل الحصف الجلدي (عدوى الجلد البكتيرية) ، والقروح الباردة (العقبول البسيط)، والقوباء المنطقية (الحلأ النطاقي)<br />والتهاب العقبول البسيط (الأكزيما العقبولية) والمليساء المعدية (التهاب جلد فيروسي)، وبثور، ودمامل.<br />&bull;تفاعلات في موضع الاستخدام مثل طفح جلدي، وألم، وإحساس بالقشعريرة، وتقشر خفيف بالجلد، وجفاف، وتورم، وزيادة حدة أعراض<br />الأكزيما.<br />آثار جانبية نادرة (تؤثر علي أقل من ١ مم كل ١٠٠٠ شخص)</p><p>&bull;احمرار، أو طفح جلدي، أو حرقان، أو حكة أو تورم بعد تناول الكحوليات بفترة قصيرة.<br />&bull;تغير في لون البشرة (تصبح أغمق أو أفتح من البشرة المحيطة)<br />تم تسجيل حالات إصابة بالسرطان، بما فيها سرطان الغدد الليمفاوية أو الجلد، لدى مرضي يستخدمون إيليدل.<br />تم تسجيل حالات تضخم الغدد الليمفاوية لدى مرضي يستخدمون إيليدل؛ ومع ذلك، لم يثبت وجود أي صلة بين ذلك والعلاج بإيليدل<br />كريم.<br />في حالة زيادة حدة أي آثار جانبية، أو إذا لاحظت وجود أي آثار جانبية غير منصوص عليها في هذه النشرة، يرجى إخبار طبيبك أو<br />الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احتفظ بهذا الدواء بعيداً عن متناول الأطفال ورؤيتهم.<br />لا تستخدم هذا الدواء بعد تاريخ الانتهاء المدون علي العبوة وعلي الأنبوبة؛ يشير تاريخ الانتهاء إلي آخر يوم في الشهر المذكور يحفظ<br />في درجة حرارة أقل من ٣٠ درجة مئوية؛ ولا تقم بتجميده.<br />يخزّن في العبوة الأصلية؛ تأكد من إغلاق الأنبوبة بإحكام.<br />عند فتح الأنبوبة ينبغي استخدامها خلال ٦ اشهر؛ ومن ثم قد يكون من المفيد تدوين تاريخ فتح الأنبوبة علي المساحة الفارغة الموجودة<br />علي العبوة.<br />لا تلق أي أدوية في مياه الصرف الصحي؛ إسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها؛ هذه الإجراءات من شأنها<br />أن تساعد علي حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-المادة الفعالة هي بيميكروليموس.<br />كل ١ جرام من إيليدل كريم يحتوي علي ١٠ ملجم من بيميكروليموس.<br />-تشتمل المكونات الأخرى علي سلسلة الدهون الثلاثية المتوسطة، وأوليل الكحول، وبروبيلين جليكول، وستياريل الكحول، وسيتيل<br />الكحول، وجليسريدات أحادية و ثنائية، وكبريتات سيتوستيريل الصوديوم، وبنزيل الكحول، وحامض الستريك اللامائي،<br />وهيدروكسيدالصوديوم، و مياه نقية.<br />شكل إيليدل كريم ومحتويات العبوة<br />إيليدل هو كريم أبيض عديم الرائحة ولا يصبغ الملابس ويسهل دعكه؛ الكريم متاح في أنبوبات<br />بحجم ٥ جم، و ١٥ جم، و ٣٠ جم، و ٦٠ جم، و ١٠٠ جم؛ ليس من الضروري أن تكون جميع تلك الأحجام متوفرة في بلدك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>&bull;مستحضر يؤثر علي صحتك وتناوله خلافا للتعليمات يعرضك للخطر.<br />&bull;اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلي الذي صرفها لك.<br />&bull;إن الطبيب والصيدلي هما الخبيران بالدواء وبنفعه و ضرره.<br />&bull;لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.<br />&bull;لا تكرر نفس الوصفة دون استشارة الطبيب.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مجلس وزراء الصحة العرب<br />إتحاد الصيادلة العرب<br />المسوق المرخص<br />ميدا للصناعات الدوائية ذات المسؤولية المحدودة<br />بنزستراس ١<br />٦ ٢٥٣١<br />بادهومبيرج<br />المانيا<br />المصنع:<br />ميدا للصناعات الدوائية<br />جادّة جي اف كنيدي<br />ميريجناك ٧٣٣٠٠</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            11/2013
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Elidel 10 mg/g cream
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 g of cream contains 10 mg of pimecrolimus.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cream.
Whitish and homogeneous.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of patients aged 2 years and over with mild or moderate atopic dermatitis where treatment with<br />topical corticosteroids is either inadvisable or not possible. This may include:<br /> Intolerance to topical corticosteroids<br /> Lack of effect of topical corticosteroids<br /> Use on the face and neck where prolonged intermittent treatment with topical corticosteroids may be<br />inappropriate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Elidel should be initiated by physicians with experience in the diagnosis and treatment of atopic dermatitis.<br />Elidel can be used in the short term for the treatment of the signs and symptoms of atopic eczema and<br />intermittently in the long term for the prevention of progression to flares.<br />Elidel treatment should begin at the first appearance of signs and symptoms of atopic dermatitis. Elidel<br />should only be applied to areas affected with atopic dermatitis. Elidel should be used for as short period as<br />possible during flares of disease. The patient or caregiver should stop using Elidel when signs and symptoms<br />resolve. Treatment should be intermittent, short-term and not continuous. Elidel should be applied thinly to<br />the affected areas twice daily.<br />Data from clinical studies support intermittent treatment with Elidel for up to 12 months.</p><p>If no improvement occurs after 6 weeks, or in case of disease exacerbation, Elidel should be stopped. The<br />diagnosis of atopic dermatitis should be re-evaluated and further therapeutic options considered.<br />Adults<br />Apply a thin layer of Elidel to the affected skin twice daily and rub in gently and completely. Each affected<br />region of the skin should be treated with Elidel until clearance occurs and then treatment should be<br />discontinued.<br />Elidel may be used on all skin areas, including the head and face, neck and intertriginous areas, except on<br />mucous membranes. Elidel should not be applied under occlusion (see section 4.4).<br />In the long-term management of atopic dermatitis (eczema), Elidel treatment should begin at first appearance<br />of signs and symptoms of atopic dermatitis to prevent flares of the disease. Elidel should be used twice daily.<br />Emollients can be applied immediately after using Elidel.<br />Paediatric population<br />The use of Elidel in patients under 2 years of age is not recommended until further data become available.<br />For children (2-11 years) and adolescents (12-17 years) the posology and method of administration are the<br />same as for adults.<br />Elderly patients<br />Atopic dermatitis (eczema) is rarely observed in patients aged 65 and over. Clinical studies with Elidel did<br />not include a sufficient number of patients in this age range to determine whether they respond differently<br />from younger patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to Pimecrolimus, other macrolactams or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Elidel cream should not be used in patients with congenital or acquired immunodeficiencies or in patients on<br />therapy that causes immunosuppression.<br />Long-term effect on the local skin immune response and on the incidence of skin malignancies is unknown.<br />Elidel should not be applied to potentially malignant or pre-malignant skin lesions.<br />Elidel should not be applied to areas affected by acute cutaneous viral infections (herpes simplex, chicken<br />pox).<br />Elidel has not been evaluated for its efficacy and safety in the treatment of clinically infected atopic<br />dermatitis. Before commencing treatment with Elidel, clinical infections at treatment sites should be cleared.<br />While patients with atopic dermatitis are predisposed to superficial skin infections including eczema<br />herpeticum (Kaposi&#39;s varicelliform eruption), treatment with Elidel may be associated with an increased risk<br />of skin herpes simplex virus infection, or eczema herpeticum (manifesting as rapid spread of vesicular and<br />erosive lesions). In the presence of herpes simplex skin infection, Elidel treatment at the site of infection<br />should be discontinued until the viral infection has cleared.<br />Patients with severe atopic dermatitis may have an increased risk of skin bacterial infections (impetigo)<br />during treatment with Elidel.<br />Use of Elidel may cause mild and transient reactions at the site of application, such as a feeling of warmth<br />and/or burning sensation. If the application site reaction is severe, the risk-benefit of treatment should be reevaluated.</p><p>Care should be taken to avoid contact with eyes and mucous membranes. If accidentally applied to these<br />areas, the cream should be thoroughly wiped off and/or rinsed off with water.<br />Physicians should advise patients on appropriate sun protection measures, such as minimisation of the time<br />in the sun, use of sunscreen product and covering the skin with appropriate clothing (see section 4.5).<br />Elidel contains cetyl alcohol and stearyl alcohol which may cause local skin reactions. Elidel also contains<br />propylene glycol, which may cause skin irritation.<br />Elidel contains the active substance pimecrolimus, a calcineurin inhibitor. In transplant patients, prolonged<br />systemic exposure to intense immunosuppression following systemic administration of calcineurin inhibitors<br />has been associated with an increased risk of developing lymphomas and skin malignancies.<br />Cases of malignancies, including cutaneous and other types of lymphoma, and skin cancers have been<br />reported in patients using pimecrolimus cream (see section 4.8). However, patients with atopic dermatitis<br />treated with Elidel have not been found to have significant systemic pimecrolimus levels.<br />In clinical studies, 14/1,544 (0.9%) cases of lymphadenopathy were reported while using Elidel 10 mg/g<br />cream. These cases of lymphadenopathy were usually related to infections and noted to resolve upon<br />appropriate antibiotic therapy. Of these 14 cases, the majority had either a clear etiology or were known to<br />resolve. Patients who receive Elidel 10 mg/g cream and who develop lymphadenopathy should have the<br />etiology of their lymphadenopathy investigated. In the absence of a clear etiology for the lymphadenopathy,<br />or in the presence of acute infectious mononucleosis, Elidel 10 mg/g cream should be discountinued. Patients<br />who develop lymphadenopathy should be monitored to ensure that the lymphadenopathy resolves.<br />Populations with potentially higher risk of systemic exposure.<br />Elidel has not been studied in patients with Netherton&rsquo;s syndrome. Due to the potential for increased<br />systemic absorption of pimecrolimus, Elidel is not recommended in patients with Netherton&#39;s syndrome.<br />As the safety of Elidel has not been established in erythrodermic patients, the use of the product in this<br />patient population cannot be recommended.<br />The use of Elidel under occlusion has not been studied in patients. Occlusive dressings are not<br />recommended.<br />In patients with severely inflamed and/or damaged skin, the systemic concentrations may be higher.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Potential interactions between Elidel and other medicinal products have not been systematically evaluated.<br />Pimecrolimus is exclusively metabolised by CYP 450 3A4. Based on its minimal extent of absorption,<br />interactions of Elidel with systemically administered medicinal products are unlikely to occur (see section<br />5.2).<br />The present data indicate that Elidel can be used simultaneously with antibiotics, antihistamines and<br />corticosteroids (oral/nasal/inhaled).<br />Based on the minimal extent of absorption, a potential systemic interaction with vaccination is unlikely to<br />occur. However, this interaction has not been studied. Therefore, in patients with extensive disease, it is<br />recommended to administer vaccinations during treatment-free intervals.<br />Application of pimecrolimus to vaccination sites, as long as local reactions persist, was not studied and is<br />therefore not recommended.<br />There is no experience with concomitant use of immunosuppressive therapies given for atopic eczema such<br />as UVB, UVA, PUVA, azathioprine and cyclosporin A.</p><p>Elidel has no photocarcinogenic potential in animals (see section 5.3.). However, since the relevance to man<br />is unknown excessive exposure of the skin to ultraviolet light including light from a solarium, or therapy<br />with PUVA, UVA or UVB should be avoided during treatment with Elidel.<br />Rare cases of flushing, rash, burning, itching or swelling have been observed shortly after the intake of<br />alcohol in patients using pimecrolimus cream (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no adequate data from the use of Elidel in pregnant women. Animal studies using dermal<br />application do not indicate direct or indirect harmful effects with respect to embryonal/fetal development.<br />Studies in animals after oral application have shown reproductive toxicity (see section 5.3). Based on the<br />minimal extent of pimecrolimus absorption after topical application of Elidel (see section 5.2), the potential<br />risk for humans is considered limited. However, Elidel should not be used during pregnancy.<br />Lactation<br />Animal studies on milk excretion after topical application were not conducted and the use of Elidel in<br />breastfeeding women has not been studied. It is not known whether pimecrolimus is excreted in the milk<br />after topical application.<br />However, based on the minimal extent of pimecrolimus absorption after topical application of Elidel, (see<br />section 5.2), the potential risk for humans is considered limited. Caution should be exercised when Elidel is<br />administered to breastfeeding women.<br />Breastfeeding mothers may use Elidel but should not apply Elidel to the breast in order to avoid<br />unintentional oral uptake by the newborn.<br />Fertility<br />There are no clinical data on the effects of pimecrolimus on male or female fertility (see section 5.3<br />Preclinical safety data).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Elidel has no known effect on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most common adverse events were application site reactions which were reported by approximately<br />19% of the patients treated with Elidel and 16% of patients in the control groups. These reactions generally<br />occurred early in treatment, were mild/moderate and were of short duration.<br />Adverse reactions are ranked under heading of frequency, the most frequent first, using the following<br />convention: very common (1/10); common (1/100, &lt;1/10); uncommon (1/1,000, &lt;1/100); rare<br />(1/10,000, &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).<br />Infections and infestations<br />Uncommon Molluscum contagiosum<br />Immune system disorders<br />Very rare Anaphylactic reactions, including severe forms<br />Metabolism and nutrition disorders<br />Rare Alcohol intolerance (in most cases, flushing, rash,<br />burning, itching or swelling occurred shortly after<br />the intake of alcohol)<br />Skin and subcutaneous tissue disorders<br />Common Skin infections (folliculitis)</p><p>Uncommon Furuncle, impetigo, herpes simplex, herpes,<br />zoster, herpes simplex dermatitis (eczema<br />herpeticum), skin papilloma and condition<br />aggravated<br />Rare Allergic reactions (e.g. rash, urticaria,<br />angiooedema), skin discoloration (e.g<br />hypopigmentation, hyperpigmentation)<br />General disorders and administration site conditions<br />Very common Application site burning<br />Common Application site reactions (irritation, pruritus and<br />erythema)<br />Uncommon Application site disorders (rash, pain,<br />paraesthesia, desquamation, dryness, oedema)</p><p>Post marketing: Cases of malignancy, including cutaneous and other types of lymphoma, and skin cancers,<br />have been reported in patients using pimecrolimus cream (see Section 4.4).<br />Cases of lymphadenopathy have been reported in post-marketing use and in clinical trials, however a causal<br />relationship with the Elidel treatment has not been established (see section 4.4).<br />To report side effect(s):<br /> Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662,<br />Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000,<br />E-mail: npc.drug@sfda.gov.sa<br /> Other GCC States:<br />- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There has been no experience of overdose with Elidel.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other dermatological preparations. Agents for dermatitis, excluding<br />corticosteroids. ATC code: D11AH02.<br />Mechanism of action<br />Pimecrolimus is a lipophilic anti-inflammatory ascomycin macrolactam derivative and a cell selective<br />inhibitor of the production and release of pro-inflammatory cytokines.<br />Pimecrolimus binds with high affinity to macrophilin-12 and inhibits the calcium-dependent phosphatase<br />calcineurin. As a consequence, it blocks the synthesis of inflammatory cytokines in T cells.<br />Pharmacodynamic effects</p><p>Pimecrolimus exhibits high anti-inflammatory activity in animal models of skin inflammation after topical<br />and systemic application. In the pig model of allergic contact dermatitis, topical pimecrolimus is as effective<br />as potent corticosteroids. Unlike corticosteroids, pimecrolimus does not cause skin atrophy in pigs and does<br />not affect Langerhans&acute;cells in murine skin.<br />Pimecrolimus neither impairs the primary immune response nor affects lymph nodes in murine allergic<br />contact dermatitis. Topical pimecrolimus penetrates similarly into, but permeates much less through human<br />skin than corticosteroids, indicating a very low potential of pimecrolimus for systemic absorption.<br />In conclusion, pimecrolimus has a skin-selective pharmacological profile different from corticosteroids.<br />Clinical efficacy and safety<br />The efficacy and safety profile of Elidel has been evaluated in more than 2,000 patients including infants<br />(3 months), children, adolescents, and adults enrolled in phase II and III studies. Over 1,500 of these<br />patients were treated with Elidel and over 500 were treated with control treatment i.e. either Elidel vehicle<br />and/or topical corticosteroids.<br />Short-term (acute) treatment:<br />Children and adolescents: Two 6-week, vehicle-controlled trials were conducted including a total of<br />403 paediatric patients aged 2 to 17 years. Patients were treated twice daily with Elidel. The data of both<br />studies were pooled.<br />Infants: A similar 6-week study was conducted in 186 patients aged 3-23 months.<br />In these three 6-week studies, the efficacy results at endpoint were as follows:</p><p>Children and adolescents Infants<br />Endpoint Criteria<br />Elidel<br />1%<br />(N=267)<br />Vehicle<br />(N=136)<br />p-value Elidel<br />1%<br />(N=123)<br />Vehicle<br />(N=63)<br />p-value<br />IGA*: Clear or almost clear 1 34.8% 18.4% &lt;0.001 54.5% 23.8% &lt;0.001<br />IGA* Improvement 2 59.9% 33% not<br />done<br />68% 40% Not done<br />Pruritus: Absent or mild 56.6% 33.8% &lt;0.001 72.4% 33.3% &lt;0.001<br />EASI&deg;: Overall (mean %<br />change)3<br />-43.6 -0.7 &lt;0.001 -61.8 +7.35 &lt;0.001<br />EASI&deg;: Head/Neck (mean %<br />change)3<br />-61.1 +0.6 &lt;0.001 -74.0 +31.48 &lt;0.001</p><p>* Investigators Global Assessment<br />&deg; Eczema Area Severity Index (EASI): mean % change in clinical signs (erythema, infiltration, excoriation,<br />lichenification) and body surface area involved<br />1: p-value based on CMH test stratified by centre<br />2Improvement=lower IGA than at baseline<br />3: p-value based on ANCOVA model of EASI at Day 43 endpoint, with centre and treatment as factors and<br />baseline (Day 1) EASI a covariate;<br />A significant improvement in pruritus was observed within the first week of treatment in 44% of children<br />and adolescents and in 70% of infants.<br />Adults: Elidel was less effective than 0.1% betamethasone-17-valerate in the short-term treatment (3 weeks)<br />of adults with moderate to severe atopic dermatitis.<br />Long-term treatment<br />Two double-blind studies of long-term management of atopic dermatitis were undertaken in 713 children and<br />adolescents (2-17 years) and 251 infants (3-23 months). Elidel was evaluated as foundation therapy.Elidel was used at first signs of itching and redness to prevent progression to flares of atopic dermatitis. Only<br />in case of a flare of severe disease not controlled by Elidel, treatment with medium potency topical<br />corticosteroids was initiated. When corticosteroid therapy was initiated for the treatment of flares, Elidel<br />therapy was discontinued. The control group received Elidel vehicle in order to maintain blinding.<br />Both studies showed a significant reduction in the incidence of flares (p&lt;0.001) in favour of Elidel treatment;<br />Elidel treatment showed better efficacy in all secondary assessments (Eczema Area Severity Index,<br />Investigators Global Assessment, subject assessment); pruritus was controlled within a week with Elidel.<br />More patients treated with Elidel completed 6 months [children (61% Elidel vs 34% control), infants (70%<br />Elidel vs 33% control)] and 12 months with no flare [children (51% Elidel vs 28% control), infants (57%<br />Elidel vs 28% control)].<br />Elidel had a sparing effect on the use of topical corticosteroids: more patients treated with Elidel did not use<br />corticosteroids in 12 months [children (57% Elidel vs 32% control), infants (64% Elidel vs 35% control)].<br />The efficacy of Elidel was maintained over time.<br />A 6-month randomized, double-blind, parallel group, vehicle-controlled study of similar design was<br />performed in 192 adults with moderate to severe atopic dermatitis. Topical corticosteroid medication was<br />used on 14.2 &plusmn; 24.2% of the days of the 24-week treatment period in Elidel group and on 37.2 &plusmn; 34.6% of the<br />days in the control group (p&lt;0.001). A total of 50.0% of the patients treated with Elidel did not experience<br />any flare compared with 24.0% of the patients randomized to the control group.<br />A one year double-blind study in adults with moderate to severe atopic dermatitis was conducted to compare<br />Elidel to 0,1% triamcinolone acetonide cream (for trunk and extremities) plus 1% hydrocortisone acetate<br />cream (for face, neck and intertriginous areas). Both Elidel and topical corticosteroids were used without<br />restrictions. Half of the patients in the control group received topical corticosteroids for more than 95% of<br />study days. Elidel was less effective than 0,1% triamcinolone acetonide cream (for trunk and extremities)<br />plus 1% hydrocortisone acetate cream (for face, neck and intertriginous areas) in the long-term treatment<br />(52 weeks) of adults with moderate to severe atopic dermatitis.<br />Long-term controlled clinical trials were 1 year in duration. There is clinical data in pediatric patients for up<br />to 24 months.<br />Frequency of application greater than twice daily has not been studied.<br />Special studies<br />Tolerability studies demonstrated that Elidel has not shown contact sensitising, phototoxic or<br />photosensitising potential, nor did they show any cumulative irritation.<br />The atrophogenic potential of Elidel in humans was tested in comparison to medium and highly potent<br />topical steroids (betamethasone-17-valerate 0.1% cream, triamcinolone acetonide 0.1% cream) and vehicle<br />in sixteen healthy volunteers treated for 4 weeks. Both topical corticosteroids induced a significant reduction<br />in skin thickness measured by echography, as compared to Elidel and vehicle, which did not induce a<br />reduction of skin thickness.</p><p>Paediatric population<br />Results of relevant studies in infants, children and adolescents are detailed above in section 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Data in animals<br />The bioavailability of pimecrolimus in mini-pigs following a single dermal dose (applied for 22h under semiocclusion)<br />was 0.03%. The amount of active substance-related material in the skin at the application site<br />(almost exclusively unchanged pimecrolimus) remained practically constant for 10 days.<br />Data in humans</p><p>Absorption in adults<br />Systemic exposure to pimecrolimus was investigated in 12 adults with atopic dermatitis who were treated<br />with Elidel twice daily for 3 weeks. The affected body surface area (BSA) ranged from 15-59%. 77.5% of<br />pimecrolimus blood concentrations were below 0.5 ng/ml and 99.8% of the total samples were below<br />1 ng/ml. The highest pimecrolimus blood concentration was 1.4 ng/ml in one patient.<br />In 40 adult patients treated for up to 1 year with Elidel, having 14-62% of their BSA affected at baseline,<br />98% of pimecrolimus blood concentrations were below 0.5 ng/ml. A maximum blood concentration of<br />0.8 ng/ml was measured in only 2 patients in week 6 of treatment. There was no increase in blood<br />concentration over time in any patient during the 12 months of treatment. In 8 adult atopic dermatitis<br />patients, in which AUC levels could be quantified, the AUC (0-12h) values ranged from 2.5 to 11.4 ng h/ml.<br />Absorption in children<br />Systemic exposure to pimecrolimus was investigated in 58 paediatric patients aged 3 months to 14 years. The<br />affected BSA ranged from 10-92%. These children were treated with Elidel twice daily for 3 weeks and five<br />out of them were treated for up to 1 year on a &ldquo;as needed&rdquo; basis.<br />Pimecrolimus blood concentrations were consistently low regardless of the extent of lesions treated or<br />duration of therapy. They were in a range similar to that measured in adult patients. Around 60% of<br />pimecrolimus blood concentrations were below 0.5 ng/ml and 97% of all samples were below 2 ng/ml. The<br />highest blood concentrations measured in 2 paediatric patients aged 8 months to 14 years were 2.0 ng/ml.<br />In infants (aged 3 to 23 months), the highest blood concentration measured in one patient was 2.6 ng/ml. In<br />the 5 children treated for 1 year, blood concentrations were consistently low (maximum blood concentration<br />was 1.94 ng/ml in 1 patient). There was no increase in blood concentration over time in any patient during<br />the 12 months of treatment.<br />In 8 paediatric patients aged 2-14 years, AUC (0-12h) ranged from 5.4 to 18.8 ng h/ml. AUC ranges observed in<br />patients with &lt;40% BSA affected at baseline were comparable to those in patients with 40% BSA.<br />The maximum body surface area treated was 92% in clinical pharmacology studies and up to 100% in Phase<br />III trials.<br />Distribution<br />Consistent with its skin selectivity, after topical application, pimecrolimus blood levels are very low.<br />Therefore pimecrolimus metabolism could not be determined after topical administration.<br />In vitro plasma protein binding studies have shown that 99.6% of pimecrolimus in plasma is bound to<br />proteins. The major fraction of pimecrolimus in plasma is bound to different lipoproteins.<br />Biotransformation<br />After single oral administration of radiolabeled pimecrolimus in healthy subjects, unchanged pimecrolimus<br />was the major active substance-related component in blood and there were numerous minor metabolites of<br />moderate polarity that appeared to be products of O-demethylations and oxygenation.<br />No metabolism of pimecrolimus was observed in human skin in vitro.<br />Elimination<br />Active substance-related radioactivity was excreted principally via the faeces (78.4%) and only a small<br />fraction (2.5%) was recovered in urine. Total mean recovery of radioactivity was 80.9%. Parent compound<br />was not detected in urine and less than 1% of radioactivity in faeces was accounted for by unchanged<br />pimecrolimus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Conventional studies of repeated dose toxicity, reproductive toxicity and carcinogenicity using oral<br />administration produced effects at exposures sufficiently in excess of those in man to be of negligible clinical<br />significance. Pimecrolimus had no genotoxic, antigenic, phototoxic, photoallergenic or photocarcinogenic</p><p>potential. Dermal application in embryo/fetal developmental studies in rats and rabbits and in carcinogenicity<br />studies in mice and rats were negative.<br />Effects on reproductive organs and altered sex hormone functions were seen in male and female rats in<br />repeated dose toxicity studies after oral administration of 10 or 40 mg/kg/day (= 20 to 60 times the maximum<br />human exposure after dermal application). This is reflected by the findings from the fertility study. The No<br />Observed Adverse Effect Level (NOAEL) for female fertility was 10 mg/kg/day (= 20 times the maximum<br />human exposure after dermal application). In the oral embryotoxicity study in rabbits, a higher resorption<br />rate associated with maternal toxicity was observed at 20 mg/kg/day (= 7 times the maximum human<br />exposure after dermal application); the mean number of live fetuses was not affected.<br />Dose-dependent increases in the incidence of lymphomas were observed at all doses in a 39 week monkey<br />oral toxicity study. Signs of recovery and/or at least partial reversibility of the effects were noted upon<br />cessation of dosages in a few animals. Failure to derive a NOAEL precludes an assessment of the margin of<br />safety between a non-carcinogenic concentration in the monkey and exposures in patients. The systemic<br />exposure at the LOAEL of 15mg/kg/day was 31 times the highest maximum exposure observed in a human<br />(paediatric patient). The risk for humans cannot be completely ruled out as the potential for local<br />immunosuppression with the long-term use of pimecrolimus cream is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medium chain triglycerides<br />Oleyl alcohol<br />Propylene glycol<br />Stearyl alcohol<br />Cetyl alcohol<br />Mono-and di-glycerides<br />Sodium cetostearyl sulphate<br />Benzyl alcohol<br />Citric acid anhydrous<br />Sodium hydroxide<br />Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 months. Use within 6 months of first opening
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C, Do not freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium tube with a phenol-epoxy protective inner lacquer and polypropylene screw cap.<br />Tubes of 5, 15, 30, 60 and 100 grams.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Emollients can be applied together with Elidel (see ection 4.2).<br />Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MEDA Pharma GmbH & Co. KG
Benzstraße 1
61352 Bad Homburg
Germany.
Tel.: (06172) 888-01
Fax: (06172) 888-27 40
E-Mail: medinfo@medapharma.de
8. MARKETING AUTHORISATION NUMBER(S)
MAH Country (Germany): 54804.00.00
Kingdom of Saudi Arabia:
15g: 2-813-12
30g: 3-813-12
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>